Zhidong Xu, Ph.D.

Associate Professor of Surgery
Division of Adult Cardiothoracic Surgery

Contact Information

2340 Sutter Street N-261, Box 1724
University of California, San Francisco
San Francisco, CA 94143-1724
(415) 514-0592 Phone
Zhidong.Xu@ucsfmedctr.org

Education

  • 1978-82, Shanghai Fisheries University, Shanghai, China, B.A., Aquaculture
  • 1984-86, Western Illinois University, Macomb, Illinois, M.S. , Biology/Cytogenetics
  • 1986-92, University of Texas Medical Branch, Galveston, TX, Ph.D., Molecular Mutagenesis

Postdoctoral Training

  • 1998-2001 , UCSF, Assistant Researcher III, Molecular Biologist
  • 1993-1998, UCSF, Cardiovascular Research Institute, Gene Therapy Core Center, Postgraduate Researcher Molecular Biologist
  • 1986-1992, The University of Texas Medical Branch, Galveston, Texas, Research Assistant
  • 1984-1986, Department of Biological Sciences, Western Illinois University, Research Assistant
  • 1982-1984, Department of Aquaculture, Shanghai Fisheries University, Shanghai, People's Republic of China, Assistant Instructor

Program Affiliations

  • Thoracic Oncology Program
  • Thoracic Oncology Laboratory
  • UCSF Helen Diller Family Comprehensive Cancer Center

Research Interests

  • Epigenetics
  • Gene expression profiling
  • Hypermethylation
  • Lung cancer
  • Mesothelioma
  • Molecularly targeted therapies
  • Monoclonal Antibody Therapy
  • Recombinant DNA technology
  • WIF-1
  • Wnt pathway

Biography

Dr. Zhidong Xu is a molecular biologist and senior scientist in the Thoracic Oncology Laboratory. Dr. Xu graduated Shanghai Fisheries University in China in 1982 with an undergraduate degree in marine aquaculture and received a masters in biology/cytogenetics in 1986 from Western Illinois University. In 1992, he received a Ph.D. in Molecular Mutagenesis from the University of Texas Medical Branch. Dr. Xu then became a post-doctoral Fellow at the Human Genome Mapping Center at UCSF, and later in the Cardiovascular Research Institute. In 1998, Dr. Xu was recruited to the Thoracic Oncology Laboratory by Dr. David Jablons and In 2001 joined the UCSF faculty.

Dr. Xu has played an important role in the expansion of the lab. Between 1999-'2001.  Dr. Xu's research on full-length cDNA cloning technology was supported by an NIH R21 grant. He is also co-PI on an NIH R01 grant, The Wnt Pathway in Malignant Mesothelioma, research that will elucidate the molecular mechanisms of malignant mesothelioma.Dr. Xu's research is focused on the molecular biology of non-small cell lung cancer and mesothelioma, including  the development of novel targeted therapeutics based on recombinant DNA technology. A summary of his overall research includes:

  • Using microarray technology for the identification of novel genes and therapeutic targets.
  • Methylation in lung carcinogenesis and as a marker in the detecting early lung cancers.
  • Elucidation of novel molecular mechanisms in the Wnt Signaling Pathway. 
  • Oncolytic viral gene therapy.
  • Development of anti-Wnt ligand monoclonal antibodies for lung cancer therapeutics
  • Development of recombinant human proteins targeting Wnt inhibitory factor 1 (WIF-1).
  • Differential gene expression profiling.

Dr. Xu has also played a critical role in forging international ties with the medical establishment in China, the goal to improve treatment lung cancer patients worldwide. Dr. Xu also helped draft the "Beijing Declaration on Lung Cancer, A Campaign for Treatment, Research and Prevention", at the 2nd North South Lung Cancer Summit in Beijing, China. He has also authored numerous peer-reviewed papers in his fields of research.  

 

Publications

Most recent publications from a total of 56
  1. Yang YL, Hung MS, Wang Y, Ni J, Mao JH, Hsieh D, Au A, Kumar A, Quigley D, Fang LT, Yeh CC, Xu Z, Jablons DM, You L. Lung tumourigenesis in a conditional Cul4A transgenic mouse model. J Pathol. 2014 Jun; 233(2):113-23. View in PubMed
  2. Hung MS, Xu Z, Chen Y, Smith E, Mao JH, Hsieh D, Lin YC, Yang CT, Jablons DM, You L. Hematein, a casein kinase II inhibitor, inhibits lung cancer tumor growth in a murine xenograft model. Int J Oncol. 2013 Nov; 43(5):1517-22. View in PubMed
  3. Liu S, Hsieh D, Yang YL, Xu Z, Peto C, Jablons DM, You L. Coumestrol from the national cancer Institute's natural product library is a novel inhibitor of protein kinase CK2. BMC Pharmacol Toxicol. 2013; 14:36. View in PubMed
  4. Bravo DT, Yang YL, Kuchenbecker K, Hung MS, Xu Z, Jablons DM, You L. Frizzled-8 receptor is activated by the Wnt-2 ligand in non-small cell lung cancer. BMC Cancer. 2013; 13:316. View in PubMed
  5. Zhang S, Long H, Yang YL, Wang Y, Hsieh D, Li W, Au A, Stoppler HJ, Xu Z, Jablons DM, You L. Inhibition of CK2a down-regulates Notch1 signalling in lung cancer cells. J Cell Mol Med. 2013 Jul; 17(7):854-62. View in PubMed
  6. Zhang S, Wang Y, Mao JH, Hsieh D, Kim IJ, Hu LM, Xu Z, Long H, Jablons DM, You L. Inhibition of CK2a down-regulates Hedgehog/Gli signaling leading to a reduction of a stem-like side population in human lung cancer cells. PLoS One. 2012; 7(6):e38996. View in PubMed
  7. Li T, Hou SC, Mao JH, Wang YC, Lu XD, Tan JL, You B, Liu YP, Ni J, Au A, Jablons DM, Xu Z, You L. The expression of Dishevelled-3 and glutamine metabolism in malignant pleural mesothelioma. J Clin Pathol. 2012 Sep; 65(9):855-8. View in PubMed
  8. Kratz JR, He J, Van Den Eeden SK, Zhu ZH, Gao W, Pham PT, Mulvihill MS, Ziaei F, Zhang H, Su B, Zhi X, Quesenberry CP, Habel LA, Deng Q, Wang Z, Zhou J, Li H, Huang MC, Yeh CC, Segal MR, Ray MR, Jones KD, Raz DJ, Xu Z, Jahan TM, Berryman D, He B, Mann MJ, Jablons DM. A practical molecular assay to predict survival in resected non-squamous, non-small-cell lung cancer: development and international validation studies. Lancet. 2012 Mar 3; 379(9818):823-32. View in PubMed
  9. Li T, Hung MS, Wang Y, Mao JH, Tan JL, Jahan K, Roos H, Xu Z, Jablons DM, You L. Transgenic mice for cre-inducible overexpression of the Cul4A gene. Genesis. 2011 Mar; 49(3):134-41. View in PubMed
  10. Hung MS, Mao JH, Xu Z, Yang CT, Yu JS, Harvard C, Lin YC, Bravo DT, Jablons DM, You L. Cul4A is an oncogene in malignant pleural mesothelioma. J Cell Mol Med. 2011 Feb; 15(2):350-8. View in PubMed
  11. View All Publications
Publications provided by UCSF Profiles, powered by CTSI at UCSF. View profile of Zhidong Xu, Ph.D.
Please note: UCSF Profiles publications are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact CTSI for help.

X